All Relations between hypertrophic and suprachiasmatic nucleus

Reference Sentence Publish Date Extraction Date Species
J S Thompson, W Sheedy, A H Moric. Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. British journal of pharmacology vol 113 issue 4 1995 7889263 Treatment with SCH 42495 caused a significant reduction in pulmonary vascular remodelling (25.0 +/- 0.01%) and right ventricular hypertrophy (0.52 +/- 0.09) in CHT20 rats compared with CHV20 controls (33.0 +/- 0.02% and 0.61 +/- 0.09 respectively). 1995-04-19 2022-01-07 rat
J S Thompson, W Sheedy, A H Moric. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clinical science (London, England : 1979) vol 87 issue 1 1994 8062513 Treatment with SCH 42495 caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days. 1994-09-22 2022-01-07 rat
I Antony, D Chemla, Y Lecarpentie. Myocardial contractility, lusitropy and calcium responsiveness in young (50 days) and hypertrophied (180 days) cardiomyopathic hamsters. Journal of molecular and cellular cardiology vol 24 issue 10 1993 1479611 Contractility, lusitropy and responsiveness to the increase of external Ca2+ concentration were studied in left ventricular papillary muscles of normal and cardiomyopathic Syrian hamsters (SCH) from the UM-X 7.1 strain, both at the onset of myolysis (50-day-old animals) and at the cardiac hypertrophy stage (180-day-old animals) in the absence of congestive heart failure. 1993-02-11 2022-01-07 Not clear
A M Richards, I G Crozier, E A Espiner, H Ikram, T G Yandle, T Kosoglou, M Rallings, C Frampto. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. Journal of cardiovascular pharmacology vol 20 issue 5 1992 1280735 The acute renal, endocrine, and hemodynamic effects of the orally active endopeptidase inhibitor SCH 34826 (400 mg every 6 hours for five doses) were investigated in a group of 6 male patients [with established mild to moderate essential hypertension and left ventricular (LV) hypertrophy] in a balanced random-order double-blind, placebo-controlled cross-over study. 1992-12-31 2022-01-07 Not clear
A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology vol 20 issue 3 1992 1279298 The effects of SCH 34826 on hypertension and left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs) were evaluated following 1 month of treatment by measuring the blood pressure, cardiac weight, and left ventricular fibrosis. 1992-12-09 2022-01-07 rat
A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology vol 20 issue 3 1992 1279298 The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. 1992-12-09 2022-01-07 rat
A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology vol 20 issue 3 1992 1279298 These data indicate that chronic inhibition of NEP by SCH 34826 interacts with mechanisms underlying myocardial hypertrophy and cardiac remodeling. 1992-12-09 2022-01-07 rat
A G Stewart, W Sheedy, J S Thompson, A H Moric. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling. Pulmonary pharmacology vol 5 issue 2 1992 1535251 Administration of SCH 34826 caused a significant reduction in the hypoxia-induced pulmonary vascular remodelling and right ventricle hypertrophy. 1992-07-24 2022-01-09 rat
A Pasternac, R Kr\\xc3\\xb3l, R Petitclerc, C Harvey, E Andermann, A Barbea. Hypertrophic cardiomyopathy in Friedreich's ataxia: symmetric or asymmetric? The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques vol 7 issue 4 1981 7194134 In contrast to reports indicating that asymmetric septal hypertrophy (ASH), often obstructive, is associated with FA, symmetric, concentric hypertrophic cardiomyopathy (SCH) was the predominant abnormality (sixty-seven percent of patients). 1981-06-23 2022-01-07 Not clear
A B Syrkin, I O Smirnova, N I Lazare. The treatment of hypertrophy of the prostate of rats with 4-nitro-3-trifluoromethylisobutyranilide (Sch 13521). Arzneimittel-Forschung vol 27 issue 7 1977 71154 The treatment of hypertrophy of the prostate of rats with 4-nitro-3-trifluoromethylisobutyranilide (Sch 13521). 1977-10-31 2022-01-07 rat
M Caine, S Perlberg, R Gordo. The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. The Journal of urology vol 114 issue 4 1977 66331 The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. 1977-05-12 2022-01-07 Not clear
Page: 
1